報價延遲最少15分鐘:2025/06/02 18:35 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.41 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.23/-0.38
|
|
企業價值
68.17M
|
| 資產負債 |
|
每股賬面淨值
1.02
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.00M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/02 18:35 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases. |